These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 12801839)

  • 1. Immunophenotypic findings in acute myeloid leukemia with FLT3 internal tandem duplication.
    Muñoz L; Aventín A; Villamor N; Juncà J; Acebedo G; Domingo A; Rozman M; Torres JP; Tormo M; Nomdedéu JF
    Haematologica; 2003 Jun; 88(6):637-45. PubMed ID: 12801839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
    Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
    Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Internal tandem duplication of fms-like tyrosine kinase 3 is associated with poor outcome in patients with myelodysplastic syndrome.
    Shih LY; Lin TL; Wang PN; Wu JH; Dunn P; Kuo MC; Huang CF
    Cancer; 2004 Sep; 101(5):989-98. PubMed ID: 15329908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia.
    Moreno I; Martín G; Bolufer P; Barragán E; Rueda E; Román J; Fernández P; León P; Mena A; Cervera J; Torres A; Sanz MA
    Haematologica; 2003 Jan; 88(1):19-24. PubMed ID: 12551822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study.
    Whitman SP; Archer KJ; Feng L; Baldus C; Becknell B; Carlson BD; Carroll AJ; Mrózek K; Vardiman JW; George SL; Kolitz JE; Larson RA; Bloomfield CD; Caligiuri MA
    Cancer Res; 2001 Oct; 61(19):7233-9. PubMed ID: 11585760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical impact of internal tandem duplications and activating point mutations in FLT3 in acute myeloid leukemia in elderly patients.
    Andersson A; Johansson B; Lassen C; Mitelman F; Billström R; Fioretos T
    Eur J Haematol; 2004 May; 72(5):307-13. PubMed ID: 15059064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical relevance of internal tandem duplication of the FLT3 gene in childhood acute myeloid leukemia.
    Liang DC; Shih LY; Hung IJ; Yang CP; Chen SH; Jaing TH; Liu HC; Chang WH
    Cancer; 2002 Jun; 94(12):3292-8. PubMed ID: 12115363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Internal tandem duplication and Asp835 mutations of the FMS-like tyrosine kinase 3 (FLT3) gene in acute promyelocytic leukemia.
    Shih LY; Kuo MC; Liang DC; Huang CF; Lin TL; Wu JH; Wang PN; Dunn P; Lai CL
    Cancer; 2003 Sep; 98(6):1206-16. PubMed ID: 12973844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different clinical importance of FLT3 internal tandem duplications in AML according to FAB classification: possible existence of distinct leukemogenesis involving monocyte differentiation pathway.
    Koh Y; Park J; Ahn KS; Kim I; Bang SM; Lee JH; Yoon SS; Soon Lee D; Yiul Lee Y; Park S; Kim BK
    Ann Hematol; 2009 Nov; 88(11):1089-97. PubMed ID: 19296110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minimal residual disease based on patient specific Flt3-ITD and -ITT mutations in acute myeloid leukemia.
    Scholl S; Loncarevic IF; Krause C; Kunert C; Clement JH; Höffken K
    Leuk Res; 2005 Jul; 29(7):849-53. PubMed ID: 15921740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detailed analysis of FLT3 expression levels in acute myeloid leukemia.
    Kuchenbauer F; Kern W; Schoch C; Kohlmann A; Hiddemann W; Haferlach T; Schnittger S
    Haematologica; 2005 Dec; 90(12):1617-25. PubMed ID: 16330434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of FLT3-ITD and D835 activating point mutations in relapsing acute myeloid leukemia and response to salvage therapy.
    Tiesmeier J; Müller-Tidow C; Westermann A; Czwalinna A; Hoffmann M; Krauter J; Heil G; Ganser A; Serve H; Verbeek W
    Leuk Res; 2004 Oct; 28(10):1069-74. PubMed ID: 15289019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Correlation of FLT3 gene expression level and internal tandem duplication mutation in acute myeloid leukemia and its clinical significance].
    Wang YG; Liu XH; Liang Y; Jin J
    Zhonghua Xue Ye Xue Za Zhi; 2008 Nov; 29(11):741-5. PubMed ID: 19176010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Importance of early detection and follow-up of FLT3 mutations in patients with acute myeloid leukemia.
    Colovic N; Tosic N; Aveic S; Djuric M; Milic N; Bumbasirevic V; Colovic M; Pavlovic S
    Ann Hematol; 2007 Oct; 86(10):741-7. PubMed ID: 17579862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flt3 internal tandem duplication and P-glycoprotein functionality in 171 patients with acute myeloid leukemia.
    Marzac C; Teyssandier I; Calendini O; Perrot JY; Faussat AM; Tang R; Casadevall N; Marie JP; Legrand O
    Clin Cancer Res; 2006 Dec; 12(23):7018-24. PubMed ID: 17145823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrant expression of CD7 in myeloblasts is highly associated with de novo acute myeloid leukemias with FLT3/ITD mutation.
    Rausei-Mills V; Chang KL; Gaal KK; Weiss LM; Huang Q
    Am J Clin Pathol; 2008 Apr; 129(4):624-9. PubMed ID: 18343790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinctive expression of myelomonocytic markers and down-regulation of CD34 in acute myelogenous leukaemia with FLT3 tandem duplication and nucleophosmin mutation.
    Mori Y; Yoshimoto G; Kumano T; Miyamoto T; Iino T; Takenaka K; Iwasaki H; Harada N; Kinukawa N; Nagafuji K; Teshima T; Shimoda K; Akashi K; Harada M
    Eur J Haematol; 2007 Jul; 79(1):17-24. PubMed ID: 17598835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy.
    Boissel N; Cayuela JM; Preudhomme C; Thomas X; Grardel N; Fund X; Tigaud I; Raffoux E; Rousselot P; Sigaux F; Degos L; Castaigne S; Fenaux P; Dombret H
    Leukemia; 2002 Sep; 16(9):1699-704. PubMed ID: 12200684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FLT3 mutations in myeloid sarcoma.
    Ansari-Lari MA; Yang CF; Tinawi-Aljundi R; Cooper L; Long P; Allan RH; Borowitz MJ; Berg KD; Murphy KM
    Br J Haematol; 2004 Sep; 126(6):785-91. PubMed ID: 15352981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of FLT3 mutations in pediatric non-promyelocytic acute myeloid leukemia.
    Kang HJ; Hong SH; Kim IH; Park BK; Han KS; Cho HI; Shin HY; Ahn HS
    Leuk Res; 2005 Jun; 29(6):617-23. PubMed ID: 15863200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.